<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endoglin (CD105), a member of transforming growth factor beta1 receptor complex, has been shown to be a more useful marker to identify <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> than panendothelial markers such as CD31 </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated endoglin and vascular endothelial growth factor (VEGF) expression as possible prognostic markers in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Surgical specimens from 75 patients with esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> treated with esophagectomy were immunostained for endoglin, CD31, and VEGF </plain></SENT>
<SENT sid="3" pm="."><plain>We also included 10 cases of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and 10 cases with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Positively stained microvessels (MVs) were counted in hot spots at magnification of x400 </plain></SENT>
<SENT sid="5" pm="."><plain>Results were expressed as the highest number of MV identified </plain></SENT>
<SENT sid="6" pm="."><plain>For VEGF, intensity of staining was scored on 3-tiered scale </plain></SENT>
<SENT sid="7" pm="."><plain>Endoglin demonstrated significantly more vessels than the CD31 (mean, 28.9 +/- 13.2 versus 19.0 +/- 9.4, P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>Both endoglin and CD31 MV counts showed significant correlation with stage of the disease (r = 0.59, P &lt; .001; r = 0.52, P &lt; .001, respectively) and patient survival (log rank P &lt; .01) </plain></SENT>
<SENT sid="9" pm="."><plain>Only endoglin MV count was significantly correlated with the presence of angiolymphatic invasion (r = 0.34, P &lt; .05) and lymph node (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e>) <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (r = 0.48, P &lt; .001) </plain></SENT>
<SENT sid="10" pm="."><plain>Univariate analysis showed that endoglin MV count is an independent prognostic factor </plain></SENT>
<SENT sid="11" pm="."><plain>Endoglin showed a significant increase in MV count in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> when compared with <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (P &lt; .01), whereas CD31 did not show any significant difference </plain></SENT>
<SENT sid="12" pm="."><plain>VEGF was expressed in 48 (64%) of 75 cases of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and was significantly correlated with angiolymphatic invasion, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, and survival </plain></SENT>
<SENT sid="13" pm="."><plain>In conclusion, endoglin is a specific and sensitive marker for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> </plain></SENT>
<SENT sid="14" pm="."><plain>Endoglin staining also showed prognostic significance with positive correlation with the presence of angiolymphatic invasion, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LN</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e>, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage, and survival </plain></SENT>
</text></document>